ClinicalTrials.gov
ClinicalTrials.gov Menu

Maternal-Offspring Metabolics:Family Intervention Trial (MOMFIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01631747
Recruitment Status : Completed
First Posted : June 29, 2012
Results First Posted : September 25, 2018
Last Update Posted : November 6, 2018
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Linda Van Horn, Northwestern University

June 25, 2012
June 29, 2012
July 26, 2018
September 25, 2018
November 6, 2018
November 2012
July 31, 2017   (Final data collection date for primary outcome measure)
Gestational Weight Gain (GWG) [ Time Frame: 14-37 weeks ]
The primary outcome is GWG as assessed continuously by the difference between the maternal weight measured at the baseline and at the 35-37 week visit.
Gestational Weight Gain (GWG) [ Time Frame: 14-36 weeks ]
The primary outcome is GWG as assessed continuously by the difference between the maternal weight measured at the 36 week visit and the self-reported pre-pregnancy weight
Complete list of historical versions of study NCT01631747 on ClinicalTrials.gov Archive Site
  • Percentage of Participants With Gestational Diabetes [ Time Frame: 24-26 weeks ]
    Oral Glucose Tolerance Test (OGTT) will be administered at 24-26wks, as part of routine obstetric visit. Difference in incidence of Gestational diabetes between study groups will be documented.
  • Fasting Glucose [ Time Frame: 14-37 wks ]
    Blood will be collected at Baseline and 35-37 weeks.
  • High-density Lipoprotein (HDL) [ Time Frame: 14-37 wks ]
    Blood will be collected at Baseline and 35-37 weeks.
  • Low-density Lipoprotein (LDL) [ Time Frame: 14-37 weeks ]
    Blood will be collected at Baseline and 35-37 weeks.
  • Total Cholesterol [ Time Frame: 14-37 Weeks ]
    Blood will be collected at Baseline and 35-37 weeks.
  • Triglycerides [ Time Frame: 14-37 Weeks ]
    Blood will be collected at Baseline and 35-37 weeks.
  • Leptin [ Time Frame: 14-37 weeks ]
    Blood will be collected at Baseline and 35-37 weeks.
  • Steady State Beta Cell Function [ Time Frame: baseline (14 weeks) and 35-37 weeks ]
    Insulin resistance will be measured with the assistance of a computer program (HOMA Calculator v2.2.3, Diabetic Trial Unit, University of Oxford) which uses blood Glucose and Insulin measures to yield the Homeostatic Model Assessment (HOMA) Steady State beta cell function (%B). 100% is set at normal reference. Should not be interpreted alone, but in combination with Insulin Sensitivity (%S).
  • Insulin Sensitivity [ Time Frame: baseline(14 weeks) and 35-37 weeks ]
    Insulin resistance will be measured with the assistance of a computer program which will yield the Homeostatic Model Assessment (HOMA) Insulin Sensitivity (%S). 100% is equivalent to the normal reference, but needs to be interpreted in context of %B.
  • Insulin Resistance (IR) [ Time Frame: Baseline (14 weeks) and 35 weeks ]
    Insulin resistance will be measured with the assistance of a computer program (HOMA Calculator v2.2.3, Diabetic Trial Unit, University of Oxford) which uses blood Glucose and Insulin measures to yield the Homeostatic Model Assessment (HOMA) Insulin Resistance. HOMA IR (insulin resistance) is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (100/%S); Lower IR is better. Note: estimates are model-derived, and not linear approximations.
  • Birth Weight [ Time Frame: Delivery ]
    Neonatal Body measurements
  • Birth Length [ Time Frame: Delivery ]
    Neonate birth measures
  • Head Circumference [ Time Frame: Delivery ]
    Neonate birth measures
  • Neonate Percent Body Fat [ Time Frame: Delivery ]
    Neonate percent body fat as measured by PeaPod, and air displacement plethysmography system.
  • Infant Weight [ Time Frame: 1 year ]
    Infant Body measurements
  • Infant Length [ Time Frame: 1 year ]
    Infant body measurement
  • Maternal Secondary Outcomes [ Time Frame: up to 40 weeks ]
    1. gestational diabetes
    2. preeclampsia
    3. cesarean delivery
    4. shoulder dystocia
    5. weight, adiposity, BP, fasting glucose, lipids, C-reactive protein, vitamin D, leptin, adiponectin
    6. Homeostatic Model Assessment (HOMA) score, a measure of insulin resistance (with the assistance of a computer program available online from the University of Oxford Diabetes Trial Unit)
    7. diet quality (diet and metabolomics assessment)
    8. physical activity
    9. sleep quality and duration
    10. measures of stress and self-efficacy
  • Fetal and Neonatal Secondary Outcomes [ Time Frame: 40 weeks ]
    1. birth weight
    2. newborn length
    3. % body fat measured by ADP
  • Infant Secondary Outcomes [ Time Frame: 1 year ]
    1. weight
    2. length
    3. head circumference
Not Provided
Not Provided
 
Maternal-Offspring Metabolics:Family Intervention Trial
Maternal-Offspring Metabolics:Family Intervention Trial (MOMFIT)
The prevalence of maternal overweight and obesity has nearly doubled in the United States since 1976. In 2004-2005, 42% of pregnant women had body mass index (BMI) above 25 versus 23% in 1993. Most American women are overweight/ obese (OW/OB) at conception, especially within certain racial, ethnic, and lower socioeconomic groups leading to increased adverse maternal and birth outcomes. This study will recruit, randomize and test in 300 ethnically diverse OW/OB pregnant women a behavioral intervention aimed at controlling gestational weight gain (GWG) through recommended diet, activity and lifestyle changes that are to be maintained postpartum. Outcomes include anthropometric (height, weight, percent body fat) metabolic (blood pressure, fasting glucose, insulin, HbA1c, lipids and C-reactive protein) and behavioral measures (diet. physical activity, sleep and stress). In addition, babies will be measured for length, weight and percent body fat. The goal is to limit excessive gestational weight gain through improved maternal lifestyle that can be maintained and modelled for the family post partum and beyond.
A Randomized Control Trial is planned among ethnically diverse OW/OB pregnant women ages 18-45 years to be randomly assigned to the MOMFIT Active Intervention Group (AIG) or the Educational Control Group (ECG) plus standard obstetrical care. The Dietary Approaches to Stop Hypertension (DASH) diet, along with moderate physical activity and group intervention as utilized in the Diabetes Prevention Program (DPP), will be adapted for pregnant and postpartum women through individual visits to tailor calorie/nutrient/activity goals, plus group coaching sessions and electronic self-monitoring behavior. Evidence based motivational interviewing and state of the art self-monitoring tools involving the LoseIt app will be adapted for pregnant/postpartum women via smartphone or Internet access, along with tailored feedback and encouragement from the Lifestyle Coach. Prevention of excessive GWG and achievement of the Institute Of Medicine (IOM) weight gain goals will be compared between groups, whether ongoing adherence to the lifestyle interventions can be sustained through postpartum intervention. Approximately one third of the participants are expected to be minorities and/or from low income backgrounds. The primary outcome is gestational weight gain from baseline (self-reported prepregnancy weight) to near delivery (36 weeks) compared with IOM goals in both groups and postpartum weight retention between 6 weeks and 12 months postpartum. Additional outcome variables include changes in maternal Body Mass Index (BMI) and adiposity postpartum, blood pressure, blood glucose, insulin, Hemoglobin A1c (HbA1c), C-reactive Protein (CRP), and lipids, diet quality, and physical activity levels, offspring adiposity and anthropometrics, and glucose and C-peptide in cord blood
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
  • Pregnancy
  • Weight Gain
  • Behavioral: Lifestyle Intervention Group
    Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
  • Behavioral: Usual Care Group
    Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
  • Active Comparator: Usual Care Group
    Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
    Intervention: Behavioral: Usual Care Group
  • Experimental: Lifestyle Intervention Group
    Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
    Intervention: Behavioral: Lifestyle Intervention Group

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
281
300
July 31, 2017
July 31, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-45 years
  • Singleton viable pregnancy. A twin pregnancy reduced to singleton before 14 weeks by project gestational age. An ultrasound must be conducted before randomization that shows a fetal heartbeat; there should be no evidence of more than one fetus on the most recent pre-randomization ultrasound.
  • Gestational age at randomization no earlier than 9 weeks 0 days and no later than 15 weeks 6 days based on an algorithm (see Section 3.4.3 below) that compares the last menstrual period (LMP) date and data from the earliest ultrasound
  • Body mass index between 25-35 kg/m2 based on first trimester measured weight and on measured height. The earliest weight measurement before randomization, measured specifically for the study will be used.

Exclusion Criteria:

  • In vitro fertilization (IVF) conception/ovulation induction w/ gonadotropins
  • Weight gain of >15 pounds from reported prepregnancy weight to Baseline visit
  • Current smoker
  • Prior bariatric surgery
  • In weight loss program w/in 3 months of conception
  • History of alcohol or drug abuse within 5 years
  • No access to internet and/or smartphone
  • Unable to attend intervention/follow-up visits
  • Unwilling/unable to commit to self-monitoring data collection
  • Unable to complete intervention program
  • Presence of any condition that limits walking or following diet recommendations
  • Not fluent in English
Sexes Eligible for Study: Female
18 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01631747
DK10-014
1U01HL114344-01 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Linda Van Horn, Northwestern University
Northwestern University
  • National Institutes of Health (NIH)
  • National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Linda V Van Horn, PhD Northwestern University
Principal Investigator: Alan Peaceman, MD Northwestern Memorial Hospital
Northwestern University
October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP